...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cardiology in review >Epidemiology of atherothrombotic disease and the effectiveness and risks of antiplatelet therapy: race and ethnicity considerations.
【24h】

Epidemiology of atherothrombotic disease and the effectiveness and risks of antiplatelet therapy: race and ethnicity considerations.

机译：动脉血栓形成疾病的流行病学以及抗血小板治疗的有效性和风险：种族和种族因素。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cardiovascular disease is the leading cause of death in the United States, accounting for approximately 60% of total mortality in 2002. There is evidence that race and ethnicity is a risk factor for atherothrombotic events. Blacks have a greater risk of complications from coronary heart disease and unstable angina, with a higher coronary heart disease death rate compared with whites. The risk of ischemic stroke is 2-4 times higher among blacks compared with whites, whereas the risk of peripheral arterial disease is highest among non-Hispanic blacks. Additionally, Asian-Pacific Islander ethnicity is an independent risk factor for bleeding, even though this ethnic group receives less antithrombotic therapy compared with whites. The increased risk of events in these patient populations may have its basis in racial and ethnic differences in the pathobiology of atherosclerosis. Some racial and ethnic populations are also inadequately prescribed antiplatelet therapy despite their higher risk. Although this difference in therapy is hard to explain, it is becoming clear that factors other than socioeconomic status or clinical presentation are influencing racial differences in physician provisions of therapy. Antiplatelet therapy, including aspirin and clopidogrel, is an important component of risk reduction strategies, and there are few data to suggest racial or ethnic variations in drug efficacies. Thus, understanding and overcoming race and ethnicity-related treatment disparities should lead to significant clinical improvements in these under-served populations.
机译：在美国，心血管疾病是主要的死亡原因，约占2002年总死亡率的60％。有证据表明，种族和种族是动脉粥样硬化血栓形成事件的危险因素。与白人相比，黑人患冠心病和不稳定型心绞痛的并发症风险更高，冠心病死亡率更高。与白人相比，黑人中缺血性中风的风险高出白人2-4倍，而非西班牙裔黑人中患外周动脉疾病的风险最高。此外，亚太岛民种族是出血的独立危险因素，尽管与白人相比，该种族人群接受的抗栓治疗较少。这些患者人群中发生事件的风险增加可能是由于动脉粥样硬化的病理生物学中种族和种族差异所致。尽管某些种族和族裔人群患病风险较高，但他们仍未充分处方抗血小板治疗。尽管这种治疗上的差异很难解释，但很明显，除了社会经济状况或临床表现外，其他因素也在影响医师在治疗中的种族差异。包括阿司匹林和氯吡格雷在内的抗血小板治疗是降低风险策略的重要组成部分，并且几乎没有数据表明种族或族裔在药物疗效方面存在差异。因此，了解和克服种族和与种族相关的治疗差异，应导致这些服务不足人群的临床显着改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号